News Related to CRH

Related coverage linked through entity extraction aliases.

Kyowa Kirin and Kura start Japanese Phase II ziftomenib trial in relapsed or refractory AML

Apr 27, 2026

Kyowa Kirin and Kura Oncology started a Japanese Phase II registrational study of ziftomenib in adults with relapsed or refractory NPM1-mutated AML. Kyowa Kirin plans to seek regulatory approval in Japan after the trial.

Moleculin Reports 40% Response Rate in Pivotal AML Trial, Unblinding Expected Q1 2026

Feb 18, 2026

Moleculin Biotech announced a preliminary blinded composite complete remission rate of 40% in the first 30 subjects of its Phase 2B/3 MIRACLE trial testing Annamycin plus cytarabine for relapsed or refractory acute myeloid leukemia.